Cross\u2010presentation by MHCI is optimally efficient in type 1 dendritic cells (DC) due to their high capacity for antigen processing. However, through specific pathways, other DCs, such as type 2 DCs and inflammatory DCs (iDCs) can also cross\u2010present antigens. Fc\u03b3R\u2010mediated uptake by type 2 DC and iDC subsets mediates antibody\u2010dependent cross\u2010presentation and activation of CD8+<\/sup>\u00a0T cell responses. Here, an important role for the p84 regulatory subunit of PI3K\u03b3 in mediating efficient cross\u2010presentation of exogenous antigens in otherwise inefficient cross\u2010presenting cells, such as type 2 DCs and GM\u2010CSF\u2010derived iDCs is identified. Fc\u03b3R\u2010mediated cross\u2010presentation is shown in type 2 and iDCs depend on the enzymatic activity of the p84\/p110\u03b3 complex of PI3K\u03b3, which controls the activity of the NADPH oxidase NOX2 and ROS production in murine spleen type 2 DCs and GM\u2010CSF\u2010derived iDCs. In contrast, p84\/p110\u03b3 is largely dispensable for cross\u2010presentation by type 1 DCs. These findings suggest that PI3K\u03b3\u2010targeted therapies, currently considered for oncological practice, may interfere with the ability of type 2 DCs and iDCs to cross\u2010present antigens contained in immune complexes.<\/p>","paragraphe_en":" Cross\u2010presentation by MHCI is optimally efficient in type 1 dendritic cells (DC) due to their high capacity for antigen processing. However, through specific pathways, other DCs, such as type 2 DCs and inflammatory DCs (iDCs) can also cross\u2010present antigens. Fc\u03b3R\u2010mediated uptake by type 2 DC and iDC subsets mediates antibody\u2010dependent cross\u2010presentation and activation of CD8+<\/sup>\u00a0T cell responses. Here, an important role for the p84 regulatory subunit of PI3K\u03b3 in mediating efficient cross\u2010presentation of exogenous antigens in otherwise inefficient cross\u2010presenting cells, such as type 2 DCs and GM\u2010CSF\u2010derived iDCs is identified. Fc\u03b3R\u2010mediated cross\u2010presentation is shown in type 2 and iDCs depend on the enzymatic activity of the p84\/p110\u03b3 complex of PI3K\u03b3, which controls the activity of the NADPH oxidase NOX2 and ROS production in murine spleen type 2 DCs and GM\u2010CSF\u2010derived iDCs. In contrast, p84\/p110\u03b3 is largely dispensable for cross\u2010presentation by type 1 DCs. These findings suggest that PI3K\u03b3\u2010targeted therapies, currently considered for oncological practice, may interfere with the ability of type 2 DCs and iDCs to cross\u2010present antigens contained in immune complexes.<\/p>","documents":null},"yoast_head":"\nAbstract<\/h2>\r\n